SAB Biotherapeutics (SABS) Interest Coverage Ratio (2021 - 2026)
SAB Biotherapeutics (SABS) posted Interest Coverage Ratio of 0.73 for Q1 2026, down 102.29% on a QoQ basis from 31.67 in Q4 2025, and up 98.24% year-over-year from 0.37 in Q1 2025.
SAB Biotherapeutics (SABS) Interest Coverage Ratio (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Interest Coverage Ratio history runs 6 years deep, the most recent figure standing at 0.73 for Q1 2026.
- Quarterly Interest Coverage Ratio rose 98.24% year-over-year to 0.73 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.11 (up 98.7% YoY) and the FY2025 annual result came in at 1.88, up 94.81% from the prior year.
- Interest Coverage Ratio was 0.73 for Q1 2026 at SAB Biotherapeutics, down from 31.67 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 487.49 in Q4 2023 and bottomed at 78.19 in Q4 2024.
- A 5-year average of 6.02 and a median of 17.4 in 2025 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio surged 6654.11% — and 2024, when it sank 963.12%.
- SAB Biotherapeutics' Interest Coverage Ratio stood at 7.44 in 2022, then jumped by 6654.11% to 487.49 in 2023, then slumped by 116.04% to 78.19 in 2024, then soared by 140.5% to 31.67 in 2025, then tumbled by 102.29% to 0.73 in 2026.
- Business Quant data shows SABS's Interest Coverage Ratio at 0.73 in Q1 2026, 31.67 in Q4 2025, and 17.4 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | -0.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.73 |
| Dec 31, 2025 | 31.67 |
| Sep 30, 2025 | -17.40 |
| Jun 30, 2025 | -13.36 |
| Mar 31, 2025 | -41.26 |
| Dec 31, 2024 | -78.19 |
| Sep 30, 2024 | -43.33 |
| Jun 30, 2024 | -41.47 |
| Mar 31, 2024 | -48.24 |
| Dec 31, 2023 | 487.49 |
| Sep 30, 2023 | -12.16 |
| Jun 30, 2023 | -3.90 |
| Mar 31, 2023 | -62.73 |
| Dec 31, 2022 | -7.44 |
| Sep 30, 2022 | -22.06 |
| Jun 30, 2022 | -3.05 |
| Mar 31, 2022 | -21.57 |
| Dec 31, 2021 | -7.99 |
| Sep 30, 2021 | -14.00 |
| Jun 30, 2021 | -10.15 |